Nizar M. Tannir, MD, discusses results from the phase 2 CANTATA study of cabozantinib plus telaglenastat in patients with advanced/metastatic renal cell carcinoma.
Nizar M. Tannir, MD, MD Anderson Cancer Center, discusses results from the phase 2 CANTATA study of cabozantinib (Cabometyx) plus either the novel glutaminase inhibitor telaglenastat (CB-839) or placebo in patients with advanced/metastatic renal cell carcinoma who progressed on immune checkpoint inhibitors or antiangiogenic therapies.
KIM-1 emerges as biomarker for MRD, atezolizumab benefit in renal cell carcinoma
June 3rd 2024Circulating kidney injury molecule-1 (KIM-1) may be a biomarker for minimal residual disease, disease recurrence, and benefit from adjuvant atezolizumab in patients with renal cell carcinoma at increased risk of recurrence, according to a retrospective analysis of the phase 3 IMmotion010 trial.